Current Edition

Upcoming Events

Advertisement

news

Roche, Adaptimmune part ways on cell therapy research

Dive Brief: Genentech, the research subsidiary of Swiss pharmaceutical giant Roche, has decided to cut short a partnership focused on cell therapies for cancer. ...
Continue Reading →
news

US sues Regeneron, alleging false price reporting on Eylea

The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for its top-selling eye drug Eyle...
Continue Reading →
news

European regulator concludes no suicide link to obesity drugs

Dive Brief: Novo Nordisk and Eli Lilly drugs to treat diabetes and obesity have no “causal association” with suicidal thoughts or incidents of suicide or self-ha...
Continue Reading →
news

Private biotech funding rises as venture firms deploy cash

Private funding for biotechnology startups rose during the first three months of the year, suggesting some of the sector’s momentum has translated to stepped-up inve...
Continue Reading →
news

Contineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs

Contineum Therapeutics has raised $110 million in an initial public offering, the biotechnology industry’s 10th of the year, to advance a group of drugs it’s develop...
Continue Reading →
news

Boehringer Ingelheim to lay off staff amid biosimilar challenges

Dive Brief: Boehringer Ingelheim is laying off staff in response to sluggish adoption of its Humira biosimilar Cyltezo, a company spokesperson confirmed to BioPh...
Continue Reading →
news

Bristol Myers CAR-T therapy approved by FDA for earlier myeloma use

Dive Brief: The Food and Drug Administration has cleared Bristol Myers Squibb and 2seventy Bio’s multiple myeloma cell therapy for earlier use treating the blood...
Continue Reading →
news

Amylyx to pull ALS drug from market in rare move

Amylyx Pharmaceuticals is pulling from market one of the few approved treatments for ALS. Rarely do drugmakers voluntarily withdraw products. In Amylyx’s case, th...
Continue Reading →
news

Medicare to cover Novo’s obesity drug for some patients

Medicare will cover the costs of Novo Nordisk’s obesity drug Wegovy for some patients with a history of heart disease, a policy shift that could significantly open u...
Continue Reading →
news

NextCure to lay off 37% of staff, dial back research plans

Cancer immunotherapy developer NextCure is laying off 37% of its staff and streamlining its research plans, the company said Thursday.  Alongside its 2023 earning...
Continue Reading →